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a b s t r a c t
Background and purpose: The Global Quality Assurance of Radiation Therapy Clinical Trials
Harmonization Group (GHG) is a collaborative group of Radiation Therapy Quality Assurance (RTQA)
Groups harmonizing and improving RTQA for multi-institutional clinical trials. The objective of the
GHG OAR Working Group was to unify OAR contouring guidance across RTQA groups by compiling a single reference list of OARs in line with AAPM TG 263 and ASTRO, together with peer-reviewed, anatomically defined contouring guidance for integration into clinical trial protocols independent of the radiation
therapy delivery technique.
Materials and methods: The GHG OAR Working Group comprised of 22 multi-professional members from
6 international RTQA Groups and affiliated organizations conducted the work in 3 stages: (1) Clinical trial
documentation review and identification of structures of interest (2) Review of existing contouring guidance and survey of proposed OAR contouring guidance (3) Review of survey feedback with recommendations for contouring guidance with standardized OAR nomenclature.
Results: 157 clinical trials were examined; 222 OAR structures were identified. Duplicates, nonanatomical, non-specific, structures with more specific alternative nomenclature, and structures identified by one RTQA group were excluded leaving 58 structures of interest. 6 OAR descriptions were
accepted with no amendments, 41 required minor amendments, 6 major amendments, 20 developed
as a result of feedback, and 5 structures excluded in response to feedback. The final GHG consensus guidance includes 73 OARs with peer-reviewed descriptions (Appendix A).
Conclusion: We provide OAR descriptions with standardized nomenclature for use in clinical trials. A
more uniform dataset supports the delivery of clinically relevant and valid conclusions from clinical
trials.
Ó 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 150 (2020) 30–39 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Clinical research in radiation therapy is conducted two-fold:
through analysis of high-level evidence generated from wellconducted prospective clinical trials, or retrospective evaluation
of real-world data extracted from big data repositories [1,2]. The
dosimetric, toxicity, and endpoint reporting parameters from these
datasets inform the development of normal tissue complication
probability (NTCP) models and define organ at risk (OAR) constraints for future radiation therapy planning protocols [3]. In these
approaches, variability in the reporting standards of OAR specific
metrics reduces the ability to draw robust conclusions and impacts
upon the validity of the recommendations [4–6].
Data pooling from institutions is impeded by inconsistencies in
nomenclature [1,7–9]. Inconsistency in contouring guidance for
OARs may increase contour variability [10]. Consistency and accuracy in structure nomenclature and contouring guidance not only
minimizes variation but also improves departmental workflow
and safety [9,11–14], with positive impact on clinician peerreview [9]. Miscommunication and lack of well-defined operating
procedures have been highlighted as key causative factors in the
origin of radiation incidents, particularly during transfers of care
[11–16]. Specific target volume (TV) and OAR radiation therapy
errors and near misses were seen in 80/1565 incidents voluntarily
reported to Public Health England (PHE) from August to November
2019 [16].
Standardization of terminology facilitates data pooling, scripting, and automation of reports; whether that is for departmental
quality assurance (QA), data capture in national registries, or wider
inter-institutional radiation therapy research. Data pooling and
data sharing agreements between investigators and institutions
makes research more efficient and increases the value of the initial
clinical trial investment [3]. Standardization of data allows robust
derivation of dose constraints and the development of dose–response relationship models [1–7].
The transition from two-dimensional radiation therapy (2D RT)
treatment planning and delivery to volumetric three-dimensional
conformal radiation therapy (3D CRT), inverse-planned intensitymodulated radiation therapy (IMRT) and proton beam radiation
therapy (PBT) has enabled dose-intensification to the TV while
sparing dose delivered to the OARs [17,18]. Inverse-planned radiation therapy is driven by user-defined planning objectives. Undercontouring of the OAR leads to inferior OAR sparing [19] with
potential for increased or unanticipated toxicity; over-contouring
could result in unnecessary dose compromises to the TV. In view
of the growing use of sequential and multi-modality anti-cancer
therapies, inaccuracies in OAR contouring and hence plan optimization risk inappropriate dose delivery to an OAR, with greater
potential for ‘‘dose-dumping” in normal tissues and subsequent
unanticipated toxicity during a patient’s treatment pathway.
The Quantitative Analyses of Normal Tissue Effects in the Clinic
(QUANTEC) review proposed OAR tolerances and defined OAR constraints; with the acknowledgement that progress in radiation
oncology accelerates only when we understand how treatment
decisions impact upon patient outcomes [1,3].
The need for consistent language and terminology has been
highlighted, as well as the positive impact of consistency on process improvement and workflow management infrastructure [9].
The international radiation therapy community continually promotes a culture of safety. Organizations including, but not limited
to, the Pennsylvania Patient Safety Authority (PSA) [11], Radiation
Oncology Safety and Education Information System (ROSEIS) [13],
Radiation Oncology Incident Learning System (RO-ILS) [15], PHE
[16], and American Society of Radiation Oncology (ASTRO) [14]
report inaccurate and incomplete communication as causative
themes in the origin of radiation incidents [16].
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The American Association of Physicists in Medicine (AAPM) has
been a driving force for the implementation of improvements in
patient safety. AAPM Task Group (TG) reports 113 [20] and 263
[2] both recommend the use of standardized nomenclature, with
the latter publishing standardized TV and OAR nomenclature,
reducing variability in naming and enabling multi-vendor platforms to interact easily.
The ASTRO Clinical Affairs and Quality Council provides guidance on which OARs should be contoured per anatomical treatment site, defining those essential OARs that consensus
recommends regardless of treatment scenario providing a basic
minimum standard of care, and those OARs which should be considered dependent on the clinical situation for contouring in
anatomical site-specific clinical trials [18].
The National Radiotherapy Trials Quality Assurance (RTTQA)
Group reported on the current provision of OAR specific contouring
guidance in United Kingdom (UK) National Institute for Health
Research Clinical Research Network (NIHR CRN) portfolio studies
[10]. Variation was seen in the OARs contoured across anatomical
site-specific clinical trials. The study found that 85.3% of OAR
specific descriptions in use within trial documentation provided
sub-optimal guidance for contouring [10].
The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group (GHG) (https://rtqaharmonization.com)
is a collaborative member group of radiation therapy QA organizations: European Organisation for Research and Treatment of Cancer
(EORTC), Imaging and Radiation Oncology Core (IROC), Japan Clinical Oncology Group (JCOG), the National Radiotherapy Trials Quality Assurance (RTTQA) Group, and Trans Tasman Radiation
Oncology Group (TROG). The GHG is also associated with the following observer groups: Australian Clinical Dosimetry Service
(ACDS), Canadian Cancer Trials Group (CCTG), European Society
for Radiotherapy and Oncology (ESTRO), International Atomic
Energy Agency (IAEA), National Physical Laboratory (NPL), Quality
and Excellence in Radiotherapy and Imaging for Children and Adolescents with Cancer across Europe in Clinical Trials (QUARTET),
and the Radiation Dosimetry Services (RDS).
The objective of the GHG is to enhance the quality of radiation
therapy in multi-institutional clinical trials through harmonization
of QA in order to reduce ambiguity in trial reporting, interpretation
and translation of clinical outcomes. The GHG identified an unmet
need for the standardization of OAR nomenclature along with
peer-reviewed contouring guidance for use in clinical trials involving adult patients with a radiation therapy component.
The GHG OAR Working Group is a multi-professional collaborative initiative, formed of twenty-two members from six international radiation therapy QA groups and affiliated organizations,
assuring broad representation across the radiation therapy
community.
The objective of the GHG OAR Working Group was to unify OAR
contouring guidance across all the QA groups by compiling a single
reference list of OARs, together with peer-reviewed, anatomically
defined contouring guidance for integration into future clinical
trial protocols independent of the radiation therapy delivery
technique.
Materials and methods
The GHG OAR Working Group conducted the work in three
stages (Fig. 1).

Stage one
Between August and November 2018 representatives of the
EORTC, IROC, RTTQA, and TROG QA groups reviewed documenta-
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specific alternatives were excluded. Structures identified by two
or more radiation therapy QA groups were included, thus creating
the ‘‘structures of interest”.

Stage two
Contouring guidance associated with each structure of interest
were collated, whether from the clinical trial protocol, an external
reference, or from a pre-existing alternative clinical trial document. The contouring guidance elements were reviewed according
to GHG OAR Working Group pre-defined objectives (Fig. 2) and
applied to each structure of interest.
Proposed contouring guidance with OAR nomenclature consistent with AAPM TG 263 [2] were created and disseminated to each
of the QA groups, who then distributed the proposed nomenclature
and contouring guidance to radiation therapy clinical trial investigators within each respective QA network. Investigators participating in the survey were instructed to provide written free-text
feedback on the proposed OAR contouring guidance.
Fig. 1. Work stages one, two, and three.

Stage three
tion from clinical trials with a radiation therapy QA component,
that were either in recruitment or in setup. Data collected
included: date of clinical trial opening, radiation therapy technique, anatomical site of radiation therapy delivery, OAR nomenclature, and associated contouring guidance.
Following application of standardized nomenclature [2], OARs
in use were collated and combined with those OARs identified as
recommended and considered for contouring from the ASTRO Clinical Affairs and Quality Council guidance [18]. Duplicates, nonanatomical, non-specific structures, and structures with more

Anonymized feedback from surveyed individuals was centrally
reviewed by the GHG OAR Working Group, reviewed against the
pre-defined objectives, and incorporated into consensus OAR contouring guidance. The proposed OAR guidelines were either;
accepted, accepted with minor amendment, or accepted with
major amendment. Major amendment involved complete revision
of the OAR description including modification of borders, whereas
minor amendment involved inclusion of omitted landmarks,
refinement of borders, or adjustment of sentence structure for user
clarity.

1.

One name and one description for each OAR$

2.

OARs are anatomically defined; the same description should be used for all treatment
scenarios

3.

OAR contouring guidance applies to adults with standard anatomy

4.

Laterality is defined on all relevant OARs

5.

Contouring guidance incorporates anatomical landmarks and border* definitions. Cranial
and caudal terminology used in preference to superior and inferior so guidance is
unambiguous regardless of patient positioning

6.

Optimal windowing and imaging modality are incorporated into contouring guidance
where relevant

7.

8.

The clinical trial protocol will define
a.

patient preparation and use of contrast

b.

patient positioning and immobilization

c.

motion management technique(s)

d.

the extent to which the OAR will be delineated beyond the limit of the PTV

Consider$ addition of ~ suffix to denote contouring of a partial structure i.e. SpinalCord~

Fig. 2. Pre-defined objectives for development of the GHG OAR Working Group consensus contouring guidance. $consistent with AAPM TG 263 recommendation; *border
definitions: cranial, caudal, medial, lateral, anterior, posterior; OAR, Organ at risk; PTV, Planning Target Volume.
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The central review process allowed exclusion of OARs and the
development of new OAR nomenclature (if not available in AAPM
TG 263) and contouring guidance in response to the survey feedback received from the international clinical community.
Ethical approval was not required when producing this consensus report.

Table 2
Examples of excluded structures.
Reason for exclusion

Structure

Comment

Non-anatomical

Bag_ostomy
Pacemaker
Bronchus_Adj
RVR
Bronchus_Main
Bronchus_L/R
Reprod^Female

Ostomy bag

Non-specific
More specific alternative
nomenclature

One hundred and fifty seven clinical trials including radiation
therapy were identified from the QA groups as recruiting or in
setup: 14 (8.9%) from EORTC, 38 (24.2%) from IROC, 84 (53.5%)
from RTTQA, and 21 (13.4%) from TROG.
The earliest clinical trial included in this analysis opened in
November 2004. Overall, 2 clinical trials included 2D RT, 61
included 3D CRT, and 103 included IMRT as the permitted radiation therapy technique(s). Stereotactic Body Radiation Therapy
(SBRT), Stereotactic Radiosurgery (SRS), and PBT were included in
the randomization(s) in 29, 3, and 7 clinical trials respectively
(Table 1).
Two hundred and six instances of OARs were identified from
the clinical trial documentation. When combined with the recommended and consider ASTRO structures, 16 additional structures
were highlighted as listed within ASTRO guidance, but not identified within clinical trial documentation. Following the exclusion of
duplicates (Table 2), 117 distinct structures remained. Exclusion of
non-anatomical, non-specific structures, structures with more
specific alternatives, and structures specified in clinical trials monitored by one or fewer radiation therapy QA groups resulted in 58
structures of interest.

Ear_L/R
Liver^Ves

Identified by one
radiation therapy QA
group

Liver vessels

18
16
Number of Structures

Results

Bronchus adjacent to PTV
Remaining volume at risk
Incorporated into Trachea and
Bronchus_Prox
Encompassing structure of the
ovary, uterus, and vagina

14
12
10
8
6
4
2
0
0

1

2
Number of QA Groups

ASTRO Recommend

3

4

ASTRO Consider

Fig. 3. QA Groups identifying each ASTRO structure.

Structures of interest
Of the 58 structures of interest, 39 (67.2%) were consistent with
the ASTRO recommended and consider OAR structures [18]. Sixteen structures were identified for contouring in the ASTRO guidance, but were not included within clinical trial documentation
from the QA groups. The cauda equina was the only structure
(Fig. 3) listed as recommended for contouring by ASTRO, which
was not described in clinical trial documentation across the QA
groups.
The brachial plexus was identified by all four radiation therapy
QA groups for contouring, but recognized as a structure only to be
considered for contouring by ASTRO for treatment involving the
cervical spine, nasopharynx, oropharynx, larynx, hypopharynx,
cervical esophagus, neck, breast, supra-clavicular fossa, axilla, or
lung.
Of the 32 ASTRO recommended structures, 30 (93.8%) were
identified in trials monitored by two or more QA groups; 17 structures (53.1%) were identified in trials monitored by all four QA
groups (Fig. 3). The ASTRO considered structures of the breast,

chest wall, great vessels, and trachea were identified by three QA
groups; genitals, hippocampus, and ovary were identified by two
QA groups.
Survey
Forty-one radiation oncologists and 6 radiation therapists (RTT)
from 38 institutions across 15 countries participated in the survey
and commented on the 58 structures of interest. The mean number
of responses per OAR was 17.72 (IQR 14–21); the surveyed participants varied by specialist site: 9 gastro-intestinal and head and
neck malignancies respectively, 7 lung, 6 breast, central nervous
system, and urological malignancies respectively, 5 sarcoma, and
4 gynae-oncology.
On review of survey responses, 6 OAR descriptions were
accepted with no amendments, 41 were accepted with minor
amendments, and 6 underwent major amendment (Fig. 4). The
existing nomenclature choices within AAPM TG 263 did not fulfill
requirements for 3 of the surveyed structures, and so new nomen-

Table 1
Anatomical treatment site and permitted radiation therapy delivery technique(s).
CNS
2D RT
BT
3D CRT
IMRT
SBRT
SRS
PBT

H&N

Thorax

Abdomen

Pelvis

Any*
2

11
15

3
24

16
20
6

9
9
6

3
2

1

2

2

1
12
31
5

10
4
12

*Radiation therapy delivery to any anatomical site; BT, Brachytherapy; CNS, Central Nervous System; H&N, Head and Neck; IMRT, Intensity-Modulated Radiation Therapy;
PBT, Proton Beam Radiation Therapy; SBRT, Stereotactic Body Radiation Therapy; SRS, Stereotactic Radiosurgery; 2D RT, Two-dimensional Radiation Therapy; 3D CRT, ThreeDimensional Conformal Radiation Therapy.
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63
ASTRO Structures

206
OAR instances from trial
documentation

222
OAR instances*

105 Duplicate structures
excluded

117 Distinct
structures

Exclusions
5 non-anatomical
11 non-specific
18 more specific
alternative nomenclature

58 Structures of
interest

25 identified by one or
fewer QA groups

Survey

6 No
amendment

41
Minor
amendment

6
Major
amendment

5
Excluded

20 Developed in
response to
survey feedback
73
OAR with peer-reviewed
descriptions
Fig. 4. OAR description survey and feedback responses. *Includes 206 OAR instances and 16 OAR structures listed within ASTRO [18] consensus guidance, which did not
appear in clinical trial documentation.

clature were created: Bronchus_Prox, FemurHeadNeck_L/R, and
LumbsacPlexs (LumbSacPlex_L/R with laterality designation).
Twenty descriptions were developed in response to survey feedback (Fig. 5), 7 of which did not have standardized nomenclature
pre-defined by AAPM TG 263 [2].
Heart
The description for the cranial border of the heart differed
between clinical trials. Six landmarks for the cranial border are in
use: superior aspect of the pulmonary artery, aorta-pulmonary
window, origin of the ascending aorta, inferior to the left pulmonary artery, point at which the pulmonary trunk and right pulmonary artery are seen as separate structures, and the
infundibulum of the right ventricle, respectively. The upper most

cranial borders were predominantly used in clinical trials pertaining to fractionated radical radiation therapy for lung cancer or
SBRT to the lung for either primary lung cancer or oligoprogressive disease, or oligometastatic disease from any primary
cancer. The point at which the pulmonary trunk and right pulmonary artery were seen as separate structures was used in clinical trials for lymphoma and primary tumors arising from the
breast.
AAPM TG report 101 [21] and UK Consensus on Normal Tissue
Dose Constraints [22] recommend the toxicity end-point for heart
irradiation in the setting of SBRT is grade 3 pericarditis. To ensure
the pericardium is encompassed fully, in the context of SBRT, the
cranial heart border is extended to the top of the pulmonary artery
to include the attachment of the fibrous pericardium at the adventitia of the great vessels [23].

R. Mir et al. / Radiotherapy and Oncology 150 (2020) 30–39
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Fig. 5. GHG consensus OAR. Treemap displaying the 73 GHG consensus OAR in dark grey and 5 excluded OAR in light grey, with classifications of no amendment, minor
amendment, major amendment, and developed in response to survey feedback. Structures in bold denote nomenclature not pre-existing within AAPM TG 263.

Considering the information above, surveyed investigators had
a preference for two of the cranial heart borders described: the
superior aspect of the pulmonary artery and the point at which
the pulmonary trunk and right pulmonary artery are seen as separate structures. In response to survey feedback and as an exception
to the pre-defined objectives (Fig. 2) two distinct heart structures
are defined within the GHG OAR consensus guidance, Heart
+A_Pulm and Heart.

dom accompanied by contouring guidance. Review of clinical and
dosimetric evaluation studies demonstrates variation in practice
[24–32]. Recommended skin thickness for contouring from clinical
trial documentation ranged from 3 to 6 mm; anatomically the
thickness of the skin is dependent on the location, ranging from
1.5 to 5 mm [33]. Contouring guidance specifies the skin structure
as a 5 mm inner rind automatically created from the external contour [34]; GHG OAR consensus guidance reflects the published
contouring guidance, with the caveat that skin thickness will vary
dependent on region of interest.

Skin
The skin structure was highlighted in clinical trial documentation or external references as ‘‘should be outlined”, ‘‘exclude”, or
‘‘include”; either in support of the radiation therapy planning
and optimization process or as a distinct OAR. This request was sel-

Bowel
The survey distributed to investigators described the bowel as
an encompassing structure from the pylorus to the recto-sigmoid
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Fig. 6. Relationship between composite and individual substructures. A, swallowing structures of the neck; B, laryngeal structures; C, the central nervous system; D, the subdiaphragmatic gastro-intestinal tract.

junction; the composite structure was reflective of the current contouring practice [10]. The overwhelming feedback from the radiation therapy community was to allow the bowel to be contoured as
individual substructures, and so Jejunum_Ileum, Bowel_Small,
Bowel_Large, Colon_Sigmoid, and Canal_Anal were defined, whilst
retaining the original Duodenum and Bowel structure. Investigators
are encouraged to choose the most appropriate structures to contour within a given treatment protocol.
Bag_Bowel nomenclature was excluded in favour of Spc_Bowel
as the nomenclature for the former was inconsistent with the associated contouring guidance [10,35].
The schematic (Fig. 6) demonstrates the relationship between
composite e.g. Bowel and individual substructures of the neck, central nervous system, and sub-diaphragmatic gastro-intestinal tract
e.g. Jejunum_Ileum, Colon_Sigmoid.
New nomenclature
The GHG OAR Working Group adopted AAPM TG 263 [2] recommendations as the nomenclature standard for this work. The existing nomenclature choices did not fulfill requirements for 10
structures; the GHG OAR central reviewers established new
nomenclature to align with currently contoured OAR (Table 3).
GHG consensus guidance on 73 OARs with standardized
nomenclature and peer-reviewed descriptions are detailed in
Appendix A; with an example of implementation of the guidance
into a clinical trial protocol.
Discussion
With the advances in the precision and delivery of radiation
therapy, the importance of accurate and consistent OAR delin-

Table 3
New nomenclature and AAPM TG 263 anatomic group.
AAPM TG 263
Anatomic
Group

New
Nomenclature

OAR

1

Eye

Anterior segment of the eye

2

Eye

3
4
5
6
7
8
9

Head &
Head &
Head &
Head &
Thorax
Thorax
Pelvis

10

Pelvis

Eye_A_L
Eye_A_R
Eye_P_L
Eye_P_R
Fossa_Pituitary
Inlet_Cricophar
Inlet_Esophagus
Musc_Cricophar
Bronchus_Prox
Heart+A_Pulm
FemurHeadNeck_L
FemurHeadNeck_R
LumbSacPlex_L
LumbSacPlex_R
LumbSacPlexs

Neck
Neck
Neck
Neck

Posterior segment of the eye
Pituitary fossa
Cricopharyngeal inlet
Esophageal inlet
Cricopharyngeal muscle
Proximal bronchial tree
Heart (extended cranial border)
Femoral head and neck
Lumbar-sacral plexus with
laterality, bilateral lumbarsacral plexus

eation cannot be understated. This GHG OAR Working Group
report from an international collaborative network of radiation
therapy QA groups provides consensus guidance on the OAR
descriptions and nomenclature for use in clinical trials, with the
aim of promoting consistency in OAR contouring and dosimetric
reporting.
Seventy-three OARs have been defined the GHG OAR Working
Group; 48 (65.8%) are included in the ASTRO Clinical Affairs and
Quality Council guidance [18]. Thirty (93.8%) of the ASTRO recommended structures were identified by two or more QA groups; 17
structures (53.1%) were identified by the four QA groups (Fig. 3),
thereby validating the consensus guidance and OAR contouring
recommendation provided by ASTRO [18].
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Six OAR descriptions underwent major amendment following
review of survey feedback (Fig. 5); the rectum, a commonly contoured OAR in urological and gynaecological clinical trials, was
one such structure. Existing rectal contouring guidance varied in
the cranial and caudal border, with use of the ischial tuberosities
as a bone surrogate for the caudal border [10]. With the move away
from 2D orthogonal radiation therapy planning, it is inaccurate to
identify soft tissue structures based on variably positioned bone
surrogates, the GHG OAR consensus guidance identifies the levator
muscles, the pubo-rectalis sling, and the disappearance of perirectal fat as landmarks for the caudal rectal border.
Five OARs were excluded in response to survey feedback; reasons for exclusion were incorporation of the OAR into alternative
nomenclature or survey respondents deeming the structure as a
TV as opposed to an OAR.
New OAR nomenclature was created for 10 structures (Table 3).
For clarity, the femoral head and neck structure is renamed as
FemurHeadNeck_L/R, the Cricopharyngeus structure is renamed as
the encompassing Inlet_Cricophar with division to the substructures Musc_Cricophar and Inlet_Esophagus to discriminate between
the muscle and inlet components (Fig. 6). The eye is subdivided
into anterior and posterior components with nomenclature consistent with AAPM TG 263 [2] guidance. The Fossa_Pituitary defines
the inner bony limits of the sella turcica, which in clinical practice
is used as an alternative structure for the Pituitary gland. The
Bronchus_Prox describes the proximal bronchial tree, a wellestablished structure when delivering SBRT to the thorax. LumbSacPlexs replaces SacralPlex as established contouring guidance is
available for the former.
The GHG OAR Working Group pre-specified objectives for the
development of consensus OAR descriptions (Fig. 2). One name
and one description should be used for each OAR. The GHG OAR
Working Group was unable to meet this objective for the heart
structure due to the variation in contouring guidance across clinical trials. As an exception, the GHG OAR Working Group has provided two heart OAR descriptions with distinct nomenclature:
Heart+A_Pulm and Heart. Clinical trial protocols and investigators
must be clear on which heart contour is used within the respective
clinical trial and use the appropriate nomenclature.
The heart as an OAR is of increasing importance. Historical series of Hodgkin’s Lymphoma survivors quantify the risk of heart
toxicity following large-field mediastinal radiation therapy
[36,37]. The Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) review of Surveillance Epidemiology and End Results
(SEER) cancer registries identified an excess of cardiac deaths following left sided versus right sided 2D planned tangential breast
radiation therapy (cardiac mortality ratio 1.58 95% CI 1.29–1.95
p = 0.03) [38]. In the context of contemporary 3D planned radical
radiation therapy delivered in the treatment of non-small cell lung
cancer and esophageal cancer, big-data analyses imply residual
shifts towards the mediastinum [39] and dose to the base of the
heart structure [40] negatively impact on overall survival. The
GHG OAR Working Group anticipates dose constraints to heart
substructures: the ventricles, atria, valves, and conduction pathways [41,42] to be prospectively evaluated in forthcoming clinical
trials.
The RTTQA Group identified the lack of OAR laterality in 54.2%
of instances of relevant nomenclature within United Kingdom clinical trials, the predominance of these OAR were within the head
and neck anatomical site [10]. AAPM TG 263 recognizes the inconsistent approach when designating OAR laterality and recommends the use of the suffix _L or _R following the primary
structure name [2]. The GHG OAR Working Group unanimously
agrees with AAPM TG 263 with the inclusion of the laterality suffix
on paired OAR over contra- or ipsi- prefix, as laterality is unambiguous, avoids non-formalized assumptions, and is logical for all
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multi-professional members of a radiation oncology department.
The application of contra- or ipsi- prefix is uncertain for midline
or bilateral TV, and laterality designation provides user clarity in
the event of TV re-irradiation.
Automated tools implementing AAPM TG 263 nomenclature,
either applied retrospectively or prospectively to institutional
datasets improve structure name compliance, with structure naming consistency reported as greater than 99.0% [43,44]. Consistency
of the guidance underlying the nomenclature choices was not evaluated; this GHG OAR consensus guidance aims to internationally
and prospectively implement a globally agreed standard for OAR
contouring.
Auto-segmentation for OAR contouring, particularly based on
deep learning algorithms are attractive; as once they have
achieved a reliable and consistent quality in OAR contouring these
processes may offer time saving efficiencies during the radiation
therapy planning process. Deep learning is reliant on consistent
expert contours over the normal variation of patient anatomies;
this GHG OAR consensus guidance defines OAR anatomically,
which could aid the generation of robust auto-segmentation models [45,46].
The impact of standardized nomenclature on treatment planning systems (TPS) and end-to-end accuracy has been estimated.
AAPM TG 263 limit OAR nomenclature to 16 characters to ensure
compatibility with the majority of TPS [2]. Three TPS compatible
special characters have been included in this consensus report:
plus, included in Heart+A_Pulm nomenclature; underscore, distinguishing OAR laterality from the primary or root name; and tilde,
designating where a structure has not been contoured in entirety
(Fig. 2). User uptake of these special characters and the impact
on compatibility between multi-vendor platforms and end-toend accuracy will be recorded with ongoing audit.
There are limitations to this work. The GHG OAR Working
Group elected to exclude structures which were not listed within
ASTRO contouring consensus guidance and were identified by
one or fewer radiation therapy QA groups; structures not frequently contoured such as the Ear_L/R and the Liver^Ves were
excluded from the stage two investigator survey. The consensus
OAR are defined in entirety; the consensus guidance may not be
suitable when overarching structures are used for optimization
and dose-reporting of substructures of variable radio-sensitivities
e.g. optimizing to the SpinalCanal structure using the doseconstraint of either the underlying SpinalCord or CaudaEquina. In
these circumstances, the GHG OAR Working Group recommend
either use of the GHG consensus contouring guidance and nomenclature or development of situation-specific clinical trial
nomenclature.
The GHG OAR Working Group consensus guideline provides
peer-reviewed contouring guidance alongside standardized
nomenclature for implementation in clinical trials. In addition to
this consensus guidance, users should employ good practice and
confirm the structure contour on all viewing planes. Image coregistration inaccuracies and artefacts affecting image quality
impact upon contouring accuracy and precision; users should be
aware of these potential sources of error and review the final contours on the primary dataset. This consensus guidance describes
each OAR in entirety; in practice, clinical trial protocols may either
specify partial OAR contouring or define the extent to which the
OAR will be contoured beyond the planning target volume (PTV).
The tilde suffix discriminates between a complete and partially
contoured OAR and on data analysis identifies the contour to
researchers as suitable for point dose measurement reporting,
and not suitable for volumetric dose reporting.
The OAR structures within this report are anatomically defined;
the GHG OAR consensus contouring guidance of whole organs is
unlikely to change. Further work and dosimetric research will

38

GHG OAR consensus contouring guidance

identify radiosensitive OAR substructures with respective dose
constraints; contouring guidance for these newly identified substructures should be developed with the engagement of the international radiation therapy community.
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